Patients with Head and Neck Cancer See Impact on Ability to Work Due to Radiotherapy

Article

In working patients with head and neck cancer receiving radiotherapy, weight loss and an increase in pain, fatigue, and ECOG status were all found to be significantly associated with reductions in working days per week.

A study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting indicated that in working patients with head and neck cancer (HNC) receiving radiotherapy (RT), weight loss and an increase in pain, fatigue, and ECOG status are all significantly associated with reductions in working days per week, with the most significant impact being pain.1

According to first author Charles Lee, MD, PharmD, a second-year resident in the department of Radiation Oncology at Fox Chase Cancer Center, these study findings are of particular importance given that many patients diagnosed with HNC are younger.2

“Of course, in younger patients, they are often working. Thus, we have a lot of time lost from work, lost productivity from patients who take time off to get daily radiation treatments for anywhere from five to seven weeks,” Lee explained. “We wanted to figure out what were factors that influenced patients taking time off from work or missing days from work during their treatments.”

For this study, researchers prospectively recorded the number of days worked in the past week at each on treatment visit for approximately 150 patients with HNC receiving definitive or adjuvant (chemo)radiation at Fox Chase Cancer Center from June 2016 to June 2018. Patients not working due to disability or unemployment were still eligible for the study, however retired patients were excluded.

Overall, 69 patients were evaluated in the study, including 40 patients who were of working age but were on disability or unemployment and 29 of whom were working at the start of RT. Of note, the mean age was higher in working patients (58.8 vs 53.7 years; P = .004).

Distance from cancer center, gender, tobacco use, alcohol use, hospitalizations during RT, presence of feeding tubes, surgery prior to RT, concurrent chemotherapy, p16 status, and location of tumor were not revealed to be significantly different between working and disabled groups. Additionally, changes in weight percentages, pain, fatigue, and ECOG status between the last on treatment visit and baseline were also not significantly different between the 2 patient groups.

However, in working patients, the mean number of days worked steadily declined, starting at 4.1 days in week 1 to 1.1 in week 7. Moreover, in univariate analysis, the investigators observed a 10% loss in weight from baseline results in 2.6 days per week lost from work (P < .005). Further, a pain increase by 1 unit was found to result in 0.25 days per week lost, fatigue increase by 1 unit resulted in 0.28 days per week lost, and ECOG status increase by 1 unit resulted in 1.48 days per week lost (P < .005 for all).

In multivariate analysis, change in pain was significantly associated with days per week lost from work (P = .05). Changes in weight (P = .08), fatigue (P = .11), and ECOG status (P = .07) were not deemed significant, however.

In the future, the researchers indicated that if these results continue to be seen in a larger cohort of patients, which they intend to collect over the next few years, then they may be able to determine which symptoms healthcare providers should prioritize to allow patients to keep working throughout treatment.

“For example, if weight loss or fatigue or pain were the most significant symptoms the patient reported that week, and they also missed 3 days of work that week, then we can say that if we treat pain better, if we mitigate weight loss better, provide better nutrition, then we can reduce the amount of productivity loss in HNC patients we’re working with,” Lee said.

References:

1. Lee CT, Deng M, Bauman J, et al. Identifying Variables Associated With Leave From Work in Head and Neck Cancer Patients Receiving Radiotherapy. Presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting. Abstract #: 3869.

2. Fox Chase Researchers Present Findings on Impact of Radiotherapy for Head and Neck Cancer on Time Off Work [news release]. Philadelphia. Published October 9, 2020. Accessed November 2, 2020. https://www.foxchase.org/news/2020-10-29-fox-chase-researchers-present-findings-on-mpact-of-radiotherapy-for-head-and-neck-cancer-on-time-off-work

Related Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.
PSMA-targeting PET ligand 18F-rhPSMA-7.3 yielded high detection rates for patients with recurrent prostate cancer regardless of factors such as PSA levels, PSA doubling time, or Gleason scores, according to Benjamin H. Lowenritt, MD, FACS.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.
Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non-small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Related Content